| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|
| FY | 199,727 | 205,129 | 206,603 | 221,986 | 225,424 | - |
| 3Q | 137,046 | 148,078 | 144,557 | 156,169 | 158,476 | - |
| 2Q | 87,240 | 102,343 | 94,349 | 103,536 | 102,784 | 108,120 |
| 1Q | 38,461 | 47,182 | 44,363 | 48,728 | 46,227 | 50,020 |
2026 2Q (6 months) ended September 30, 2025
Overall sales increased 5.2% over the same period of the previous fiscal year. In Japan, the Company concentrated on enhancing sales activities which match each market; the acute care hospital market, the small and mid-sized hospital market, and the clinic market. The Company also focused on its consumables and services business as well as strengthening its marketing and service capabilities, creating customer value which contributed to improving medical safety, patient outcomes, and operating efficiency. As a result of these measures, domestic sales increased, while capital expenditure in hospitals was cautious. Sales of Physiological Measuring Equipment increased favorably. Sales of Treatment Equipment and Other Medical Equipment remained flat, while sales of Patient Monitors decreased. Internationally, sales in North America, Europe, and Asia & Other increased favorably. Overseas sales achieved double-digit growth on a comparable basis excluding the currency effect and the impact of the consolidation of Ad-Tech. Sales of Physiological Measuring Equipment increased significantly. Sales of Treatment Equipment also achieved double-digit growth. Sales of Patient Monitors and Other Medical Equipment increased on a local currency basis and decreased on a yen basis.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|
| FY | 27,094 | 30,992 | 21,120 | 19,591 | 20,713 | - |
| 3Q | 15,586 | 23,316 | 11,377 | 10,515 | 10,935 | - |
| 2Q | 8,758 | 17,414 | 7,217 | 7,491 | 5,114 | 6,741 |
| 1Q | 1,831 | 6,423 | 1,817 | 2,205 | -1,248 | 1,400 |
2026 2Q (6 months) ended September 30, 2025
Operating income increased 31.8%, due to increased sales and the consolidation of Ad-Tech. The increase in operating income was also because of favorable gross profit margin due to higher selling prices and cost reductions of in-house products, as well as a decrease in inventory devaluation.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|
| FY | 28,374 | 34,563 | 24,122 | 25,589 | 20,373 | - |
| 3Q | 14,697 | 24,677 | 13,937 | 13,258 | 13,506 | - |
| 2Q | 8,215 | 17,990 | 13,019 | 12,546 | 2,139 | 6,732 |
| 1Q | 1,581 | 6,743 | 5,481 | 5,794 | 1,674 | 473 |
2026 2Q (6 months) ended September 30, 2025
Ordinary income increased 214.7%, reflecting lower foreign exchange losses.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|
| FY | 18,243 | 23,435 | 17,110 | 17,026 | 14,098 | - |
| 3Q | 8,882 | 16,911 | 8,860 | 7,926 | 8,137 | - |
| 2Q | 5,826 | 12,294 | 8,541 | 7,997 | 463 | 4,524 |
| 1Q | 1,060 | 4,537 | 3,679 | 3,787 | 766 | 137 |
2026 2Q (6 months) ended September 30, 2025
Income attributable to owners of parent increased 876.7%.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|
| FY | 214.21 | 276.51 | 203.28 | 101.23 | 84.88 | - |
| 3Q | 104.30 | 199.36 | 105.25 | 47.10 | 48.77 | - |
| 2Q | 68.42 | 144.85 | 101.43 | 47.53 | 2.76 | 27.74 |
| 1Q | 12.46 | 53.38 | 43.66 | 22.51 | 4.57 | 0.84 |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|
| FY | 193,030 | 210,201 | 216,728 | 233,233 | 258,276 | - |
| 3Q | 170,521 | 191,981 | 206,011 | 215,788 | 246,286 | - |
| 2Q | 168,512 | 189,754 | 209,292 | 220,990 | 218,600 | 246,579 |
| 1Q | 161,362 | 180,514 | 203,115 | 216,444 | 223,787 | 247,066 |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|
| FY | 138,986 | 156,381 | 167,604 | 181,082 | 181,294 | - |
| 3Q | 127,733 | 150,175 | 161,242 | 171,479 | 177,694 | - |
| 2Q | 126,853 | 147,144 | 162,424 | 174,305 | 176,385 | 173,815 |
| 1Q | 121,577 | 139,525 | 156,453 | 169,587 | 179,211 | 177,528 |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|
| FY | 72.0 | 74.4 | 77.3 | 77.6 | 69.5 | - |
| 3Q | 74.9 | 78.2 | 78.3 | 79.5 | 72.1 | - |
| 2Q | 75.3 | 77.5 | 77.6 | 78.9 | 80.7 | 70.5 |
| 1Q | 75.3 | 77.3 | 77.0 | 78.4 | 80.1 | 71.2 |
Caution
-
These data are prepared based on the financial results reports.
-
The frequency of updates may change in accordance with changes to the format of the financial results reports.
-
Please see the financial results reports and other materials for detailed information regarding the settlement of accounts.
-
The contents of these data will not immediately reflect corrections to the financial results reports when announced.
-
While we pay due caution to the conversion of data for the posting, please note that there is a possibility that errors may occur in the information due to uncontrollable circumstances, such as the unauthorized alteration of contents by a third party or mechanical defects resulting from equipment malfunction.
-
Service provided by Nomura Investor Relations Co., Ltd.
Powered by ShareWith
